VRTX Soars on Strong CF Sales and New Product Push

Vertex Pharmaceuticals (VRTX) reported fiscal 2025 Q4 earnings on Feb 12, 2026, with revenue rising 9.5% to $3.19 billion and net income surging 30.5% to $1.19 billion. The company exceeded revenue estimates by $20 million and provided 2026 guidance in line with analyst expectations, signaling confidence in its growth trajectory.

Revenue

Product revenues, net, led the way with $3.19 billion, driven primarily by TRIKAFTA/KAFTRIO, which accounted for $2.57 billion. ALYFTREK contributed an additional $380.10 million, while other product revenues added $237.40 million. The performance underscores the company’s dominance in cystic fibrosis and successful expansion into new therapeutic areas.

Earnings/Net Income

Vertex Pharmaceuticals’s EPS rose 32.1% to $4.69 in 2025 Q4 from $3.55 in 2024 Q4, while net income grew by 30.5% to $1.19 billion. The significant EPS growth and robust net income increase underscore Vertex Pharmaceuticals' strong earnings performance.

Post-Earnings Price Action Review

The strategy of buying Vertex Pharmaceuticals shares after its revenue raised q/q on the financial report release date and holding for 30 days delivered strong returns over the past three years, achieving an overall return of 88.43%—surpassing the benchmark by 33.22%. The CAGR of 17.29% highlights consistent growth, though the strategy faced a maximum drawdown of 30.90% during market downturns, reflecting volatility. A Sharpe ratio of 0.64 indicates moderate risk-adjusted returns, balancing growth potential with inherent market risks.

CEO Commentary

Reshma Kewalramani emphasized Vertex’s 10% Q4 revenue growth, driven by CF leadership with ALYFTREK, new product launches like CASGEVY and JOURNAVX, and pipeline advancements. Strategic priorities include expanding CF dominance, accelerating CASGEVY adoption, and advancing the renal franchise, particularly povetacicept for IgA nephropathy. The CEO’s tone remained optimistic, highlighting Vertex’s focus on high-unmet-need diseases and transformative therapies.

Guidance

Vertex guided to 2026 full-year revenue of $12.95–$13.1 billion (8–9% growth), with non-CF products expected to contribute $500 million or more. Combined non-GAAP operating expenses are projected at $5.65–$5.75 billion, a tax rate of 19.5–20.5%, and Q1 2026 revenue growth of ~7%. The guidance assumes robust CASGEVY adoption and continued pipeline progress.

Additional News

Vertex Pharmaceuticals advanced its therapeutic pipeline with the commercialization of CASGEVY (gene therapy for sickle cell disease) and JOURNAVX (opioid-sparing therapy for chronic pain). The company also progressed povetacicept, a candidate for IgA nephropathy, into late-stage trials. These innovations align with CEO Kewalramani’s focus on diversifying Vertex’s commercial footprint beyond cystic fibrosis.